Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO5469754 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| RO5469754 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Single doses, iv or sc |
| RO5469754 | DRUG | Single ascending doses, iv or sc |
Inclusion Criteria: * Healthy male or female volunteers, 18 to 64 years of age, inclusive * Body mass index (BMI) 18 to 32 kg/m2 * Women of child-bearing potential and their partners must be willing to use two highly effective forms of contraception, one of which must be a barrier method, for the e...
RO5469754 is an investigational small molecule developed by Roche Holding AG. It has been studied in a Phase 1 clinical trial in healthy volunteers. The specific disease or condition it is intended to treat has not been disclosed, and it remains in early clinical development.
RO5469754 is being developed by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche is the sponsor of the clinical program for this investigational small molecule.
RO5469754 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA.
RO5469754 has been evaluated in one completed Phase 1 trial, NCT01620931, titled A Single-Ascending-Dose Study of RO5469754 in Healthy Volunteers. The trial enrolled 36 healthy adult participants in the Netherlands and used a randomized, placebo-controlled design.
The therapeutic use of RO5469754 has not been disclosed. Its only reported clinical study was a Phase 1 single-ascending-dose trial conducted in healthy volunteers, so no patient population or indication has been publicly identified for this investigational small molecule.